Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defining CD95 as a tumor suppressor gene.

M Müschen1, U Warskulat, M W Beckmann

  • 1Institute of Genetics, Department of Immunology and Medizinische Klinik I, Universität zu Köln, Cologne, Germany. markus.mueschen@uni-koeln.de

Journal of Molecular Medicine (Berlin, Germany)
|September 23, 2000
PubMed
Summary

The CD95 (Apo-1/Fas) receptor system regulates apoptosis and lymphocyte balance. Mutations in the CD95 gene increase tumor risk, suggesting CD95 acts as a tumor suppressor, while CD95L expression promotes cancer progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Importance of parametric and molecular imaging for therapeutic management of breast cancer].

Radiologie (Heidelberg, Germany)·2024
Same author

Replies - Letter to the Editor - "Effect of a comprehensive lifestyle intervention program on body weight and health behavior in women with breast cancer: Results from a randomized controlled trial".

Clinical nutrition (Edinburgh, Scotland)·2024
Same author

Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer.

ESMO open·2024
Same author

The German Network for Personalized Medicine to enhance patient care and translational research.

Nature medicine·2023
Same author

Determinants of transplantation success with cryopreserved ovarian tissue: data from 196 women of the FertiPROTEKT network.

Human reproduction (Oxford, England)·2022
Same author

Quality assurance and improvement in oncology using guideline-derived quality indicators - results of gynaecological cancer centres certified by the German cancer society (DKG).

Journal of cancer research and clinical oncology·2022

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • The CD95 (Apo-1/Fas) receptor-ligand system is crucial for apoptosis and lymphocyte homeostasis.
  • Tumor cells often exhibit reduced susceptibility to CD95-mediated apoptosis.
  • Mutations in the CD95 gene are linked to increased risk of lymphoid and solid tumors.

Purpose of the Study:

  • To discuss the role of CD95 as a tumor suppressor gene.
  • To explore the implications of CD95 ligand (CD95L) expression in malignant progression.
  • To analyze the significance of CD95 and CD95L expression in tumor development.

Main Methods:

  • Literature review and conceptual discussion.
  • Analysis of evidence linking CD95 mutations to cancer risk.

Related Experiment Videos

  • Examination of studies on CD95L expression in various tumor types.

    • Main Results:

    • CD95 mutations are associated with high risks of lymphoid and solid tumors.
    • Malignant cells often express CD95L aberrantly, inducing apoptosis in bystander cells.
    • Neoplastic CD95L expression contributes to local tissue destruction, invasion, and metastasis.

    Conclusions:

    • CD95 functions as a tumor suppressor gene.
    • Aberrant CD95L expression by tumors promotes malignant progression and immune evasion.
    • Dysregulation of the CD95 system (loss of CD95, gain of CD95L) is significant for tumor progression.